CMPX
NASDAQCompass Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
News · 26 weeks49-87%
2025-12-142026-06-07
Mix1890d
- SEC Filings6(33%)
- Other6(33%)
- Insider4(22%)
- Earnings1(6%)
- Analyst1(6%)
Latest news
25 items- PRCompass Therapeutics to Participate in Upcoming June Investor EventsBOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of June. Details are as follows: Jefferies Global Healthcare ConferenceDate: Thursday, June 4, 2026 Time: 8:45 AM ETWebcast Link: https://cmpx.info/jefferies Goldman Sachs 47th Annual Global Healthcare ConferenceDate: Tuesday, June 9, 2026 Time: 8:00 AM ETWebcast Link: https://cmpx.info/gs Virtual/Replay availability: Presentations will be archived on Compass' Ev
- PRCompass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual MeetingCTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with advanced malignancies resistant to prior immune checkpoint inhibitors.Deep and durable responses were observed in patients with triple-negative breast cancer (TNBC), Hodgkin lymphoma (HL), and non-small cell lung cancer (NSCLC).CTX-8371 was generally well tolerated with no observed dose limiting toxicities (DLTs). BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based th
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Compass Therapeutics Inc.SCHEDULE 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)
- PRCompass Therapeutics to Participate in Upcoming May Investor EventsBOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of May. Details are as follows: H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ Date: Tuesday, May 19, 2026 Time: 1:30 PM ETWebcast Link: https://journey.ct.events/view/bc55d2f9-d121-4f7d-8129-1f69f201bd7f 2026 Stifel Virtual Targeted Oncology ForumDate: Wednesday, May 20, 2026 Time: 11:30 AM ETWebcast Link: https://event.summitcast.com/view/SS
- SECSEC Form 10-Q filed by Compass Therapeutics Inc.10-Q - Compass Therapeutics, Inc. (0001738021) (Filer)
- SECCompass Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Compass Therapeutics, Inc. (0001738021) (Filer)
- PRCompass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate UpdateAs recently announced, tovecimig (DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement in progression-free survival (PFS) versus paclitaxel alone as well as clear signals of a survival benefit in a Phase 2/3 study of patients with biliary tract cancer (BTC); tovecimig previously met the primary endpoint of overall response rate (ORR). Tovecimig received Orphan Drug Designation in April and the Company intends to meet with the FDA in advance of its planned BLA submission later this year.The Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody) has been selected for a poster presentation at the Amer
- INSIDERAmendment: Chief Accounting Officer Lerner Neil bought $28,350 worth of shares (15,000 units at $1.89), increasing direct ownership by 4% to 397,500 units (SEC Form 4)4/A - Compass Therapeutics, Inc. (0001738021) (Issuer)
- INSIDERAmendment: General Counsel Anderman Jonathan bought $47,250 worth of shares (25,000 units at $1.89), increasing direct ownership by 15% to 196,000 units (SEC Form 4)4/A - Compass Therapeutics, Inc. (0001738021) (Issuer)
- INSIDERGeneral Counsel Anderman Jonathan was granted 25,000 shares, increasing direct ownership by 15% to 196,000 units (SEC Form 4)4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
- INSIDERChief Accounting Officer Lerner Neil was granted 15,000 shares, increasing direct ownership by 4% to 397,500 units (SEC Form 4)4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
- SECSEC Form DEFA14A filed by Compass Therapeutics Inc.DEFA14A - Compass Therapeutics, Inc. (0001738021) (Filer)
- SECSEC Form DEF 14A filed by Compass Therapeutics Inc.DEF 14A - Compass Therapeutics, Inc. (0001738021) (Filer)
- ANALYSTCompass Therapeutics downgraded by Raymond JamesRaymond James downgraded Compass Therapeutics from Outperform to Mkt Perform
- SECCompass Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Compass Therapeutics, Inc. (0001738021) (Filer)
- PRTovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract CancerTovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement versus paclitaxel alone in the key secondary endpoint of median progression-free survival (PFS) of 4.7 months versus 2.6 months, providing a 56% reduction in the risk of progression (hazard ratio=0.44, p<0.0001). Secondary endpoint analyses of overall survival (OS) were confounded by both high crossover (54%) and notably prolonged survival in crossover patients randomized to the control arm then treated with tovecimig and, therefore, did not meet statistical significance. In a subset analysis of the patients in the control arm, the median OS of the crosso
- PRCompass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract CancerWebcast scheduled for Monday, April 27, 2026 at 8:00am ET. BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on Monday, April 27, 2026 at 8:00am ET to review topline secondary endpoints from its Phase 2/3 COMPANION-002 clinical study assessing tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer (BTC). Conference Call and Webcast Presentation: Date and Time: Monday, April 27, 2026 at 8:00am ET Toll Fre
- SECSEC Form S-8 filed by Compass Therapeutics Inc.S-8 - Compass Therapeutics, Inc. (0001738021) (Filer)
- SECSEC Form 10-K filed by Compass Therapeutics Inc.10-K - Compass Therapeutics, Inc. (0001738021) (Filer)
- SECCompass Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Compass Therapeutics, Inc. (0001738021) (Filer)
- PRCompass Therapeutics Reports 2025 Financial Results and Provides Corporate UpdateIn the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified event threshold of 80% overall survival (OS) events was reached in Q1 2026; as a result, the analyses of progression-free survival (PFS) and OS are expected to be reported in April. Based on previously reported responses in patients with triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC) in the Phase 1 study of CTX-8371 (PD-1 x PD-L1 bispecific antibody), expansion cohorts are now open and enrolling patients with these tumor types; based on an additional response in a patient with Hodgkin lymphoma, a further expansion cohort of
- PRBiliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsightLAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/OHARA Pharmaceutical), Tovecimig (CTX-009) (Compass Therapeutics), Lenvatinib mesylate (LENVIMA) (Merck/Eisai), and others will further boost the market growth. Recently published Biliary Tract Cancer Market Insights report includes a comprehensive understanding of current
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Compass Therapeutics Inc.SCHEDULE 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)
- ANALYSTCraig Hallum initiated coverage on Compass Therapeutics with a new price targetCraig Hallum initiated coverage of Compass Therapeutics with a rating of Buy and set a new price target of $15.00
- INSIDERCHIEF EXECUTIVE OFFICER Schuetz Thomas J. covered exercise/tax liability with 36,687 shares, decreasing direct ownership by 0.55% to 6,603,336 units (SEC Form 4)4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
CMPX FAQ
6 questionsWhat does Compass Therapeutics Inc. do?
Compass Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing antibody therapeutics to treat solid tumors and hematologic malignancies. The company is leveraging its proprietary StitchMabs and common light-chain enabled multi specific platforms to identify multi specifics and combinations of antibody therapeutics that could be advanced to the clinic. Its lead product candidate is CTX-471, a monoclonal antibody agonist of CD137, a co-stimulatory receptor on immune cells that is being evaluated in a Phase 1 study in patients who were previously treated with...Where does CMPX stock trade?
Compass Therapeutics Inc. (CMPX) is listed on NASDAQ.What sector and industry is CMPX in?
Compass Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about CMPX?
Compass Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Raymond James: Mkt Perform on 2026-04-28. Recent price targets range from $600.00 to $1500.00.What companies are similar to CMPX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare CMPX side-by-side with any of them on Quantisnow.How can I track CMPX on Quantisnow?
Quantisnow aggregates Compass Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CMPX to receive live email and push alerts on every new disclosure.